MacGowan J R, Pringle J, Morris V H, Stamp T C
Division of Bone and Mineral Metabolism, Royal National Orthopaedic Hospital, Stanmore, Middlesex, UK.
Skeletal Radiol. 2000 May;29(5):279-82. doi: 10.1007/s002560050608.
Inhibition of skeletal mineralisation is a well-recognized complication of disodium etidronate therapy that was identified in the earliest studies of its use in osteoporosis and Paget's disease. The effect is seen at lower doses in Paget's disease than in osteoporosis. Several cases of spontaneous fractures occurring in unaffected bones of Paget's patients have been reported. However, we believe the case described here is the most severe example of etidronate-induced osteomalacia published in the literature, featuring widespread vertebral collapse occurring as a consequence of nearly 10 years of uninterrupted etidronate treatment for isolated hemipelvic Paget's disease.
抑制骨骼矿化是依替膦酸二钠治疗中一种公认的并发症,在其用于骨质疏松症和佩吉特病的最早研究中就已被发现。在佩吉特病中,这种效应在较低剂量时就可见到,而在骨质疏松症中则不然。已有报道称,佩吉特病患者未受影响的骨骼发生了几例自发性骨折。然而,我们认为此处描述的病例是文献中报道的依替膦酸导致骨软化最严重的例子,其特征是因对孤立性半侧骨盆佩吉特病进行了近10年不间断的依替膦酸治疗而出现广泛的椎体塌陷。